MOOVE
Moove, the global mobility fintech that democratises access to vehicle ownership for mobility entrepreneurs, today announces that it has raised $100 million in a Series B funding round, valuing the company at $750m. Uber invested in the round alongside Mubadala, who led Moove’s previous funding round in 2023.
The round will enable Moove to expand its customer focused revenue-based vehicle financing offering to 16 markets around the world by the end of 2025. A considerable portion of this expansion will focus on electric vehicles (EVs), which will lay the groundwork for a more sustainable and accessible mobility ecosystem for its customers worldwide.
Ladi Delano, Founder of Moove, said: “Today’s announcement marks a significant milestone for us. When we founded Moove in 2020, we were motivated to solve the acute shortage of vehicle financing that over two million African mobility entrepreneurs faced.
“This validation from Uber and others stands as a testament to the fact that what was once a dream is now a palpable reality. This infusion of capital is set to amplify the immensely positive impact our products have in the lives of our customers on a much broader spectrum. I would like to extend my heartfelt gratitude to our dedicated team of Moovers for their relentless effort and commitment, which has been pivotal in reaching this significant milestone on our company’s journey.”
Moove was founded in 2020 to connect mobility entrepreneurs with fair, accessible, and affordable revenue-based vehicle financing options. Now based in its new headquarters in the UAE, an emerging nexus for entrepreneurship and innovative startups, the evolving partnership between Moove and Mubadala stands as a prime example of how collaboration between local UAE investors and startups can catalyse growth and innovation both within the UAE and globally.
The UAE stands as a pivotal market for Moove, as it was the first market where Moove launched its fully integrated charging solution, investing in a network of charging stations exclusively for Moove customers. Additionally, the UAE was Moove's pioneer market for transitioning to a 100% EV fleet, leading to the company providing the largest number of EV trips on the Uber UAE platform in 2023. This strategic focus on sustainability and innovation underscores Moove's commitment to shaping the future of mobility in the region and supporting the UAE's vision for economic diversification and technological advancement.
To date, Moove has helped more than 20,000 mobility entrepreneurs across three continents, enabling more than 30 million Moove financed trips – resulting in an annual recurring revenue of over $115 million, a significant milestone on the path to profitability.
Ali Eid Al Mheiri, Executive Director of UAE Diversified Assets at Mubadala’s UAE Investments Platform, commented: “We are proud to continue supporting Moove through our second round of funding, not only as a testament to our commitment to nurturing the startup ecosystem in the UAE but also as a reflection of our renewed trust in Moove's vision and capabilities. This follow-on investment exemplifies Mubadala’s strategy of deploying capital to drive positive change in communities, in addition to fostering innovation and entrepreneurship across the UAE.”
Ladi Delano concluded: "This recent investment is a game-changer for Moove, enabling us to substantially broaden our offerings by introducing 45,000 new vehicles to our platform. This funding milestone not only expands our operational capacity but also supports our drive to profitability by the next financial year. We are committed to building Moove in a sustainable, customer focused and profitable way. Moove’s aim is to be at the forefront of the electrification of mobility, which we believe will help steer the world towards a zero-emission future."
BofA Securities acted as financial adviser to Moove.
About Moove
Moove is a global mobility fintech that is democratising access to financial services for mobility entrepreneurs. It does this by embedding its alternative credit scoring technology onto ride-hailing platforms, using proprietary performance and revenue analytics to underwrite customers that have previously been excluded from financial services. Moove operates in 9 markets across Africa, Middle East, Europe and Asia. Its customers have completed more than 30 million trips in Moove-financed vehicles to date.
Key facts
- Moove has positively impacted the lives of over 80,000 people, globally
- Moove has served over 20,000 Moove customers since its inception
- Over 30 million trips in Moove financed cars
- Over $250m equity raised, and over $210m debt funding raised since inception
- Achieved $115m ARR in 2023
Notes to the Editor
- Investors participating in the round include Uber as well as existing investors Mubadala, The Latest Ventures, Africinvest, Palm Drive Capital, Triatlum Advisors AG, and Future Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319308732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom